Moderna, Inc MRNA Stock Price, News, Quote & History

According to 17 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $82.07, which is an increase of 89.15% from the latest price. He projected Recursion will offer more information on cost-cutting when it reports fourth quarter 2024 results early in the new year. Earlier this month, the company swung to a surprise profit and topped revenue estimates for the third quarter following the launch earlier this year of its updated COVID-19 vaccine. “We expect to end the year with $9 billion in cash,” Talukdar said, according to a transcript provided by AlphaSense. “Our investment rate … is declining each year going forward. And we anticipate that $9 billion will have us launching 10 products over the next three years that will start to contribute to revenue a year after approval.”

After Moderna’s Shocking News, Is the Stock a Buy or a Sell?

Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after buying an additional 29,566 shares during the period. ARK Investment Management LLC grew its position in shares of Moderna by 10.4% during the 3rd quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after buying an additional 109,852 shares during the last quarter.

• Finally, HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th.
• Last month, the company revised coronavirus vaccine revenue downward due to lower sales.
• Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter.
• Moderna is not the only company working on mRNA, but it is the company’s focus, and therefore it can put all its resources toward that technology.
• The bad news is that Moderna will take longer than originally expected to get to the break-even point.

MarketBeat All Access Features

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… Marks cited FDA cooperation with Operation Warp Speed initiative, through which Trump’s first administration shepherded development of COVID-19 vaccines through funding of trials and manufacturing.

Recent News: MRNA

But flu vaccines, COVID shots, and RSV vaccines may not be enough to make the business profitable in the long run. Moderna (MRNA 3.19%) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with revenue from its vaccine diminishing and no longer being a strong growth catalyst, investors have become bearish on the healthcare stock.

Why Is Moderna, Inc. (MRNA) Among the Worst Performing Healthcare Stocks in 2024?

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively. Discover which analysts rank highest on predicting the oanda broker directional movement of MRNA.

In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market. However, Moderna is developing a robust pipeline that could propel the company for the foreseeable future. Is that pipeline strong enough to warrant buying the stock now, or should investors sit on the sidelines and wait? Before the COVID-19 pandemic, most investors likely hadn’t heard of Moderna (MRNA 3.19%).

Nearly four years later, the company is in a curious spot as it still has only one commercially available product. Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. In the 2024 presidential election’s latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme…

Latest investing news

This is different than traditional vaccines where a harmless version of a virus or bacteria is used to trigger an immune response. Moderna had been working on this technology for nearly a decade before the pandemic broke out, putting the company in a position to get a vaccine to market very quickly. However, last month, Moderna surprised analysts by reporting net income of $13 million (up from a $3.63 billion net loss in Q3 2023) and higher-than-expected sales of its COVID-19 vaccine Spikevax® ($1.8 billion). Yet the unexpected profit wasn’t enough to stave off a drop in Moderna shares. Unlock your free copy of MarketBeat’s gold mining stocks comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you’ll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street’s top analysts.

According to a 2021 study, Operation Warp Speed spent over $18 billion dollars of U.S. public funds on six vaccine candidates, including Moderna’s SpikeVax, the subject of a $1.5 billion agreement announced in August 2020 to manufacture and deliver 100 million doses. There’s no doubt that the success of the COVID-19 vaccine was proof that mRNA technology is a viable path to pursue for Moderna, which took a lot of the risk out of an investment in the company. That said, it’s worth remembering that this is a very difficult and accentforex broker review capital-intensive business, with binary outcomes for the drugs that take millions of dollars to develop. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. But it’s important to take a long-term view with Moderna, and also look at some of its positive points. It’s good to see the company prioritizing and adjusting its strategy to reach its goals — even if certain ones, like breakeven, won’t come as soon as we’d hoped.

Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Select to analyze similar companies using key performance metrics; select up to 4 stocks. “If you listen to where his stance is on vaccines most recently, so starting— dating from 2022 and as recently as shortly after the election results, he is a lot more moderate than I would have thought,” she said.